SLC1A5 and breast carcinoma: In conclusion, our findings suggested that the contribution of SLC1A5 expression in luminal breast cancer and failure of endocrine treatment might be through participation in the pentose phosphate pathway via regulation of TALDO1 expression essential for cancer cells growth and proliferation.